CONTEXT: Aging is associated with declining gonadal steroid production, low bone mineral density (BMD), and fragility fractures. The efficacy and safety of testosterone replacement in older men remains uncertain. OBJECTIVE: The objective of the study was to assess the effects of aromatase inhibition on BMD in older men with low testosterone levels. DESIGN AND SETTING: This was a 1-yr, double-blind, randomized, placebo-controlled trial that was conducted at a tertiary care academic center in Boston, MA. PARTICIPANTS: Participants included 69 men aged 60+ yr with borderline or low testosterone levels and hypogonadal symptoms. INTERVENTION: Intervention included 1 mg anastrozole daily or placebo. MAIN OUTCOME MEASURES: Changes in gonadal steroid hormone levels, BMD, and bone turnover markers were measured. RESULTS:Mean serum testosterone increased from 319 +/- 93 ng/dl at baseline to 524+/-139 ng/dl at month 3 (P < 0.0001) and declined slightly to 474 +/- 145 ng/dl by 1 yr. Estradiol levels decreased from 15 +/- 4 pg/ml at baseline to 12 +/- 4 pg/ml at month 3 and then remained stable (P < 0.0001). Posterior-anterior (PA) spine BMD decreased in the anastrozole group as compared with placebo (P = 0.0014). In the anastrozole group, PA spine BMD decreased from 1.121 +/- 0.141 g/cm(2) to 1.102 +/- 0.138 g/cm(2), whereas in the placebo group, PA spine BMD increased from 1.180 +/- 0.145 g/cm(2) to 1.189 +/- 0.146 g/cm(2). Qualitatively similar, but not statistically significant, changes occurred at the other sites. Bone turnover markers were not affected by anastrozole therapy. CONCLUSIONS: In older men, aromatase inhibition increases testosterone levels, decreases estradiol levels, and appears to decrease BMD. Aromatase inhibition does not improve skeletal health in aging men with low or low normal testosterone levels.
RCT Entities:
CONTEXT: Aging is associated with declining gonadal steroid production, low bone mineral density (BMD), and fragility fractures. The efficacy and safety of testosterone replacement in older men remains uncertain. OBJECTIVE: The objective of the study was to assess the effects of aromatase inhibition on BMD in older men with low testosterone levels. DESIGN AND SETTING: This was a 1-yr, double-blind, randomized, placebo-controlled trial that was conducted at a tertiary care academic center in Boston, MA. PARTICIPANTS: Participants included 69 men aged 60+ yr with borderline or low testosterone levels and hypogonadal symptoms. INTERVENTION: Intervention included 1 mg anastrozole daily or placebo. MAIN OUTCOME MEASURES: Changes in gonadal steroid hormone levels, BMD, and bone turnover markers were measured. RESULTS: Mean serum testosterone increased from 319 +/- 93 ng/dl at baseline to 524+/-139 ng/dl at month 3 (P < 0.0001) and declined slightly to 474 +/- 145 ng/dl by 1 yr. Estradiol levels decreased from 15 +/- 4 pg/ml at baseline to 12 +/- 4 pg/ml at month 3 and then remained stable (P < 0.0001). Posterior-anterior (PA) spine BMD decreased in the anastrozole group as compared with placebo (P = 0.0014). In the anastrozole group, PA spine BMD decreased from 1.121 +/- 0.141 g/cm(2) to 1.102 +/- 0.138 g/cm(2), whereas in the placebo group, PA spine BMD increased from 1.180 +/- 0.145 g/cm(2) to 1.189 +/- 0.146 g/cm(2). Qualitatively similar, but not statistically significant, changes occurred at the other sites. Bone turnover markers were not affected by anastrozole therapy. CONCLUSIONS: In older men, aromatase inhibition increases testosterone levels, decreases estradiol levels, and appears to decrease BMD. Aromatase inhibition does not improve skeletal health in aging men with low or low normal testosterone levels.
Authors: P J Snyder; H Peachey; P Hannoush; J A Berlin; L Loh; J H Holmes; A Dlewati; J Staley; J Santanna; S C Kapoor; M F Attie; J G Haddad; B L Strom Journal: J Clin Endocrinol Metab Date: 1999-06 Impact factor: 5.958
Authors: Christina Wang; Glenn Cunningham; Adrian Dobs; Ali Iranmanesh; Alvin M Matsumoto; Peter J Snyder; Thomas Weber; Nancy Berman; Laura Hull; Ronald S Swerdloff Journal: J Clin Endocrinol Metab Date: 2004-05 Impact factor: 5.958
Authors: K Sreekumaran Nair; Robert A Rizza; Peter O'Brien; Ketan Dhatariya; Kevin R Short; Ajay Nehra; Janet L Vittone; George G Klee; Ananda Basu; Rita Basu; Claudio Cobelli; Gianna Toffolo; Chiara Dalla Man; Donald J Tindall; L Joseph Melton; Glenn E Smith; Sundeep Khosla; Michael D Jensen Journal: N Engl J Med Date: 2006-10-19 Impact factor: 91.245
Authors: Dan Mellström; Olof Johnell; Osten Ljunggren; Anna-Lena Eriksson; Mattias Lorentzon; Hans Mallmin; Anna Holmberg; Inga Redlund-Johnell; Eric Orwoll; Claes Ohlsson Journal: J Bone Miner Res Date: 2006-04-05 Impact factor: 6.741
Authors: Henrik G Ahlborg; Olof Johnell; Charles H Turner; Gunnar Rannevik; Magnus K Karlsson Journal: N Engl J Med Date: 2003-07-24 Impact factor: 91.245
Authors: Sherri-Ann M Burnett-Bowie; Kristen C Roupenian; Melissa E Dere; Hang Lee; Benjamin Z Leder Journal: Clin Endocrinol (Oxf) Date: 2009-01 Impact factor: 3.478
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: Chevon M Rariy; Sarah J Ratcliffe; Rachel Weinstein; Shalender Bhasin; Marc R Blackman; Jane A Cauley; John Robbins; Joseph M Zmuda; Tamara B Harris; Anne R Cappola Journal: J Clin Endocrinol Metab Date: 2011-02-02 Impact factor: 5.958
Authors: Joel S Finkelstein; Hang Lee; Benjamin Z Leder; Sherri-Ann M Burnett-Bowie; David W Goldstein; Christopher W Hahn; Sarah C Hirsch; Alex Linker; Nicholas Perros; Andrew B Servais; Alexander P Taylor; Matthew L Webb; Jonathan M Youngner; Elaine W Yu Journal: J Clin Invest Date: 2016-02-22 Impact factor: 14.808
Authors: Margaret A Gates; Rania A Mekary; Gretchen R Chiu; Eric L Ding; Gary A Wittert; Andre B Araujo Journal: J Clin Endocrinol Metab Date: 2013-04-26 Impact factor: 5.958